Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	VEGFA	Synonyms	L-VEGF, MVCD1, VEGF, VPF	Type of gene	protein-coding
Chromosome	6	Map location	6p21.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	vascular endothelial growth factor A

GTO ID	GTC0095
Trial ID	NCT01100307
Disease	Retinal Disease \| Macular Edema \| Diabetic Mellitus
Altered gene	VEGFA
Therapeutic/Target gene	Target gene
Therapy	Aptamer
Treatment	Macugen\|pegaptanib\|EYE001
Phase	Phase3
Recruitment status	Completed
Title	A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium, With Sham Injections, And Open Study (For 30 Weeks) To Confirm The Safety Of 0.3 MG Pegaptanib Sodium In Subjects With Diabetic Macular Edema (DME)
Year	2010
Country	Japan
Company sponsor	Pfizer
Other ID(s)	A5751034

Cohort1: Pegaptanib Sodium_double masked phase

Administration route	intravitreal injection
Dosage	Pegaptanib sodium, 0.3 milligrams, every 6 weeks, Total number of injections were 4 times in the double masked phase (up to Week 24)
Pts	123
Age	Adult, Older_Adult
Adverse reactions	10/123(Ear and labyrinth disorders; Eye disorders; Gastrointestinal disorders; Hepatobiliary disorders; Infections and infestations; Metabolism and nutrition disorders; Nervous system disorders)

Cohort2: Sham_double masked phase

Administration route	intravitreal injection
Dosage	Sham injection, every 6 weeks, Total number of injections were 4 times in the double masked phase (up to Week 24)
Pts	120
Age	Adult, Older_Adult
Adverse reactions	10/120(Blood and lymphatic system disorders; Cardiac disorders; Eye disorders; Gastrointestinal disorders; Infections and infestations; Musculoskeletal and connective tissue disorders; Nervous system disorders)

Cohort3: Pegaptanib Sodium_double masked phase_open phase

Administration route	intravitreal injection
Dosage	Pegaptanib sodium, 0.3 milligrams, every 6 weeks, Total number of injections were 4 times in the double masked phase (up to Week 24); Pegaptanib sodium, 0.3 milligrams, every 6 weeks, 5 times in the open phase (from Week 24 to Week 54)
Pts	123
Age	Adult, Older_Adult
Adverse reactions	19/123(Cardiac disorders; Ear and labyrinth disorders; Eye disorders; Gastrointestinal disorders; Hepatobiliary disorders; Infections and infestations; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders)

Cohort4: Sham_double masked phas_Pegaptanib Sodium_open phase

Administration route	intravitreal injection
Dosage	Pegaptanib sodium, 0.3 milligrams, every 6 weeks, Total number of injections were 5 times in the open phase (Week 24 to Week 54)
Pts	112
Age	Adult, Older_Adult
Adverse reactions	7/112(Cardiac disorders; Eye disorders; Infections and infestations; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders)

Overview of Knowledge Graph